Agios is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare hematologic and metabolic diseases, with core expertise in cellular metabolism and classical hematology. The company's primary asset is mitapivat, a first-in-class pyruvate kinase activator approved for pyruvate kinase deficiency, thalassemia, and in development for sickle cell disease and other blood disorders, supported by a pipeline of early-stage programs targeting additional rare conditions such as myelodysplastic syndromes, phenylketonuria, and polycythemia vera. Agios generates revenue through direct commercialization in the United States via its own sales force, distribution partnerships in Europe and the Gulf region, managed access programs, and royalty arrangements, while maintaining global supply chains through third-party manufacturers.